您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > BAY-1895344
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
BAY-1895344
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
BAY-1895344图片
CAS NO:1876467-74-1
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
500mg电议

产品介绍
BAY-1895344 (BAY-1895344) 是一种有效的、具有口服活性的选择性 ATR 抑制剂,IC50 为 7 nM。 BAY-1895344 具有抗肿瘤活性。 BAY-1895344 可用于实体瘤和淋巴瘤的研究。
Cas No.1876467-74-1
别名BAY 1895344
Canonical SMILESCN1N=CC=C1C2=CC(N3[C@H](C)COCC3)=NC4=C(C5=NNC=C5)N=CC=C24
分子式C20H21N7O
分子量375.43
溶解度DMSO: 5.4 mg/mL (14.38 mM)
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

BAY-1895344 is a potent, orally available and selective ATR inhibitor, with IC50 of 7 nM. Anti-tumor activity[1].

BAY-1895344 potently inhibits the proliferation of a broad spectrum of human tumor cell lines with a median IC50 of 78 nM[1].BAY-1895344 potently suppresses hydroxyurea-induced H2AX phosphorylation (IC50, 36 nM)[1].

BAY-1895344 shows potent anti-tumor efficacy in monotherapy in a variety of xenograft models of ovarian and colorectal cancer, and causes complete tumor remission in mantle cell lymphoma models[2].

[1]. Ulrich T. Luecking, et al. Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models. Cancer Research. July 2017 Volume 77, Issue 13 Supplement. [2]. Antje Margret Wengner, et al. Abstract 836: ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride in preclinical tumor models. Cancer Research. July 2017 Volume 77, Issue 13 Supplement